Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lip and Oral Cavity Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
18 drugs · 80 active trials
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cisplatin | Phase 3 | Phase 3 | 18 | 8 | 8 | 42 | 0 | — | — | 1999-07 |
| Pembrolizumab | Phase 3 | Phase 3 | 16 | 8 | 2 | 19 | 0 | — | — | 2015-11 |
| Carboplatin | Phase 3 | Phase 3 | 12 | 4 | 5 | 19 | 0 | — | — | Apr 25, 2007 |
| Paclitaxel | Phase 3 | Phase 3 | 7 | 3 | 2 | 10 | 0 | — | — | Apr 25, 2007 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 5 | 0 | 1 | 6 | 0 | — | — | Mar 26, 2013 |
| Cetuximab | Phase 3 | Phase 3 | 4 | 3 | 5 | 22 | 0 | — | — | 2005-01 |
| Fluorouracil | Phase 3 | Phase 3 | 4 | 2 | 4 | 12 | 0 | — | — | 1999-07 |
| Docetaxel | Phase 3 | Phase 3 | 3 | 1 | 5 | 13 | 0 | — | — | 2002-09 |
| Durvalumab | Phase 3 | Phase 3 | 2 | 0 | 1 | 8 | 0 | — | — | 2017-01 |
| Bevacizumab | Phase 3 | Phase 3 | 2 | 0 | 2 | 6 | 0 | — | — | 2001-07 |
| Sintilimab | Phase 3 | Phase 3 | 2 | 1 | 1 | 4 | 0 | — | — | Aug 15, 2019 |
| Toripalimab | Phase 3 | Phase 3 | 2 | 2 | 1 | 4 | 0 | — | — | Jul 30, 2020 |
| Atezolizumab | Phase 3 | Phase 3 | 2 | 0 | 1 | 2 | 0 | — | — | Mar 13, 2023 |
| Metformin | Phase 3 | Phase 3 | 1 | 0 | 1 | 5 | 0 | — | — | Jun 10, 2016 |
| Cyclophosphamide | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2010-12 |
| Hydroxyurea | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2001-07 |
| Aspirin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | May 17, 2023 |
| Erlotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Nov 3, 2006 |
| Nivolumab | Phase 2 | Phase 2 | 5 | 1 | 0 | 13 | 0 | — | — | 2016-03 |
| Tislelizumab | Phase 2 | Phase 2 | 4 | 1 | 0 | 4 | 0 | — | — | May 8, 2023 |
| Cemiplimab | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Nov 30, 2021 |
| Cabozantinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Sep 18, 2018 |
| Ipatasertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 26, 2022 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 1 | 1 | 0 | 9 | 0 | — | — | 2001-12 |
| Camrelizumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Apr 23, 2020 |
| Capecitabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2009-10 |
| Celecoxib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2013-11 |
| Ipilimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jan 30, 2017 |
| Methotrexate | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 9, 2025 |
| Olaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 15, 2017 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 2, 2025 |
| Sorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 25, 2007 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Aug 6, 2010 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-06 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-09 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-11 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-09 |
| Abiraterone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 13, 2023 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2012 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-05 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-02 |
| Dacomitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-05 |
| Dasatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-07 |
| Doxorubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-06 |
| Enzalutamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 13, 2023 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 21, 2020 |
| Porfimer | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2014 |
| Tegafur | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 26, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.